GHCM
MDGL icon

Glen Harbor Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Glen Harbor Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-68
Closed -$8K – 1335
2019
Q1 		$8K Hold
68
– – ﹤0.01% 1295
2018
Q4 		$8K Buy
+68
New +$10.5K ﹤0.01% 1267

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Glen Harbor Capital Management's MDGL Position: Q2 2019 in Review

Glen Harbor Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2019, closing a stake of 68 shares — an estimated $8K sold.

Glen Harbor Capital Management first reported a position in MDGL in Q4 2018 and held it in 2 quarters. The position peaked at $8K in Q1 2019. 116 funds tracked by Wall St. Rank hold MDGL as of Q2 2019.

  • Glen Harbor Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Glen Harbor Capital Management sold 68 Madrigal Pharmaceuticals shares in Q2 2019, an estimated $8K.
  • Glen Harbor Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Glen Harbor Capital Management's Madrigal Pharmaceuticals position peaked at $8K in Q1 2019.
  • 116 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2019.

Based on Glen Harbor Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.